Calibrating Microglia States in Alzheimer's Disease: From Anti-Amyloid Antibodies to Multi-Target Microenvironment Protection
核心洞察
Anti-Aβ monoclonal antibodies lecanemab and donanemab provide statistically significant disease modification but offer only modest cognitive benefit and carry ARIA risks, underscoring that amyloid clearance alone is insufficient.
Microglia are now recognized as central determinants of AD susceptibility and progression, existing along dynamic continua shaped by the TREM2 (搜索)–APOE axis, complement-mediated synaptic pruning, and immunometabolic reprogramming.
The phase II failure of the TREM2 (搜索) agonist AL002 illustrates that receptor activation alone cannot overcome broader network dysfunction when lipid overload, complement dysregulation, and metabolic exhaustion are advanced.
The treatment paradigm for Alzheimer's disease (搜索) is undergoing a fundamental shift—from a singular focus on removing amyloid pathology toward a more nuanced strategy of regulating the brain's immune microenvironment. Two recent anti-Aβ monoclonal antibodies, lecanemab and donanemab, have decisively changed the field by demonstrating that amyloid lowering achieves statistically significant disease modification in early symptomatic AD. Yet their cognitive benefits remain modest, and adverse events such as amyloid-related imaging abnormalities (ARIA) require careful monitoring. These findings confirm that amyloid clearance is clinically relevant but not sufficient for full restoration of neuroimmune, metabolic, synaptic, and neurovascular balance.
Microglia as Central Hubs in AD Pathogenesis
Genomic studies have firmly established that key late-onset AD risk genes—including TREM2 (搜索), CD33, MS4A6A, CR1, PLCG2, INPP5D, and ABCA7—are enriched in microglia, positioning these cells as active determinants of disease susceptibility and progression rather than passive responders. Single-cell transcriptomics and spatial omics have dismantled the outdated M1/M2 polarization framework, revealing that microglia in AD occupy continuous, dynamic state spaces shaped by plaque proximity, disease stage, genotype, age, sex, and tissue context.
A comprehensive review published in Frontiers in Immunology identifies three core mechanistic axes driving microglial dysfunction: the TREM2 (搜索)–APOE lipid-sensing axis, complement-mediated synaptic elimination, and immunometabolic reprogramming encompassing glycolysis, mitochondrial damage, autophagy failure, and NAD+ depletion.
The TREM2 (搜索)–APOE Axis and the Goldilocks Principle
TREM2 (搜索) functions as a decisive damage- and lipid-sensing receptor that sustains microglial survival, lipid processing, lysosomal function, and Aβ phagocytosis. Loss-of-function TREM2 mutations sharply elevate AD risk. However, TREM2 signaling follows a Goldilocks-like principle: too little signaling is harmful, while excessive or mis-timed signaling is also maladaptive.
The phase II failure of the TREM2 (搜索) agonistic antibody AL002—despite evidence of target engagement and increased soluble TREM2 in earlier studies—powerfully illustrates this principle. As the review authors note, "activating one receptor cannot overcome the broader disease network if lipid overload, complement dysregulation, mitochondrial dysfunction, and cellular exhaustion are already advanced." In lipid-overloaded or lysosome-compromised microglia, further receptor stimulation may increase substrate uptake without improving degradation, thereby aggravating intracellular stress.
Complement-Mediated Synaptic Pruning
Synaptic loss, an early and clinically relevant feature of AD, is driven in part by the reactivation of complement-dependent pruning pathways. Oligomeric Aβ and inflammatory cues trigger excessive deposition of microglia-derived C1q on vulnerable synapses, activating the classical complement cascade and leading to CR3-dependent phagocytosis of opsonized synapses. Protective "don't eat me" signals, such as the CD47–SIRPα pathway, and complement regulators like CD55 and CD59 normally set a threshold for synaptic preservation. When these brakes are overwhelmed, complement activation becomes excessive and synaptotoxic.
Immunometabolic Reprogramming and the Vicious Cycle
Chronic Aβ and tau stress stabilizes HIF-1α, promoting PKM2-driven glycolysis and creating a brain-resident analog of the Warburg effect. This metabolic shift suppresses AMPK, permits aberrant mTORC1 activity, and uncouples the AMPK–mTORC1–ULK1 axis, disrupting autophagic flux. As mitophagy falters, damaged mitochondria accumulate, and oxidized mitochondrial DNA leaks into the cytosol, activating cGAS–STING signaling and triggering type I interferon responses. Concurrently, chronic PARP-1 activation depletes NAD+, reducing both oxidative metabolism and sirtuin-mediated repair. Together, these processes trap microglia in a state defined by high glycolysis, low respiration, and persistent inflammation.
Toward Escort-Style Combination Therapy
The review proposes an "escort" strategy in which anti-Aβ antibodies remain the primary mechanism for pathology clearance, while adjunctive interventions stabilize the immune-metabolic-vascular microenvironment. Potential escort agents include metabolic modulators such as metformin, mitochondrial protectants such as coenzyme Q10, carefully timed autophagy modulators, pro-resolving anti-inflammatory agents, and nanodelivered natural bioactive molecules.
Crucially, this strategy demands biomarker-driven calibration. Patients with high amyloid burden, APOE ε4 genotype, cerebral amyloid angiopathy, or baseline microbleeds may benefit from vascular-protective and complement-buffering strategies. Those with elevated inflammatory markers or increased glial activation signals may need low-intensity immunomodulatory support. Individuals with metabolic dysfunction may be better suited for metabolic or lysosome-supporting interventions.
The endpoint of escort therapy should not be maximal suppression of inflammatory biomarkers, but rather amyloid reduction with stable blood-brain barrier integrity, absence or reduction of ARIA, preservation of synaptic and neuronal injury markers, and maintenance of adaptive microglial responses.
Clinical Translation Challenges
Despite advances in experimental nanodelivery systems, Alzheimer's nanomedicine is not ready for clinical use. Concerns include CNS toxicity, immune activation, lack of consistent human data, manufacturing complexity, and bystander uptake by non-microglial cells. Similarly, multicomponent natural therapies face barriers of low oral bioavailability, limited brain exposure, and pharmacological noise.
The review authors emphasize that future research must prioritize spatial characterization of microglial states, human validation using iPSC-derived microglia and chimeric models, integration of sex as a biological variable, and optimization of treatment sequencing—for instance, restoring lysosomal function before inducing autophagy in lipid-overloaded microglia.
As the field moves forward, microglial state recalibration represents more than a refinement of anti-inflammatory therapy. It embodies a shift from suppressing disease signals to restoring functional homeostasis, with the goal of transitioning microglia from maladaptive disease-amplifying states to protective, adaptive, and tissue-supportive roles.